Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-CD40 Antibody-FITC (9S211) is a FITC-conjugated Mouse antibody targeting CD40. Anti-CD40 Antibody-FITC (9S211) can be used in FCM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 T | $81 | 7-10 days | |
| 100 T | $176 | 7-10 days |
| Description | Anti-CD40 Antibody-FITC (9S211) is a FITC-conjugated Mouse antibody targeting CD40. Anti-CD40 Antibody-FITC (9S211) can be used in FCM. |
| Synonyms | TRAP, Tnfrsf5, T-BAM, p50, IMD3, Igm, HIGM1, gp39, CD40 molecule, TNF receptor superfamily member 5, Bp50, AI326936 |
| Ig Type | Mouse IgG2b |
| Clone | 9S211 |
| Reactivity | Human |
| Specificity | Human CD40/TNFRSF5 |
| Verified Activity | Profile of CD40 reactivity on Daudi cells analyzed by flow cytometry. Cells should be Fc-blocked by treatment with 10 μg of human IgG/106 cells for 1 hour at 4°C prior to staining, washed, then stained with FITC Mouse anti-CD40. |
| Application | |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD40 / TNFRSF5 (rh CD40 / TNFRSF5; TMPY-01181; NP_001241.1; Met 1-Arg 193) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | CD40, also known as TNFRSF5, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins. CD40 protein plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 protein is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3). In addition, CD40/CD40L interaction is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | FITC |
| Others Formats | Unconjugated/APC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human CD40 protein (TMPY-01181) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.